ROTH Capital Partners Acts as Sole Book-Running Manager
for Bionano Genomics, Inc. (Nasdaq: BNGOU)
in its $20.6 Million IPO


For more information please contact:

Investment Banking
Eric B. Cheng
Managing Director
Co-Head of Healthcare
Investment Banking
(646) 358-1901

James Antonopoulos
Managing Director
Co-Head of Healthcare
Investment Banking
(646) 358-1906

Equity Capital Markets
Aaron Gurewitz
Head of Equity
Capital Markets
(949) 720-5703
Nazan Akdeniz
Senior Vice President
(949) 720-5740
Lou Ellis
Senior Vice President
(949) 720-5739

Transaction Information
Bionano Genomics, Inc. (Nasdaq: BNGOU), a life sciences instrumentation company that develops and markets Saphyr, a platform for ultra-sensitive and ultra-specific structural variation detection in genome analysis, has completed its initial public offering of 3,360,000 units at a public offering price of $6.125 per unit, resulting in the gross proceeds for Bionano Genomics, Inc. of approximately $20.6 Million. Each unit consists of one share of common stock and a five-year warrant to purchase one share of common stock at an initial exercise price of $6.125 per share. In addition, Bionano has granted the underwriters a 30-day option to purchase up to 504,000 additional units at the initial public offering price.

The units began trading on The Nasdaq Capital Market under the ticker symbol “BNGOU” on August 21, 2018. On or prior to September 21, 2018, the units will separate into each of its components and each such component security will begin trading separately on The Nasdaq Capital Market. The common stock is expected to trade under the symbol “BNGO,” while the warrants are expected to trade under the ticker symbol “BNGOW.” Bionano will issue a press release announcing the date such separate trading will begin.

ROTH Capital Partners acted as sole book-running manager for the offering.

About Bionano Genomics
Bionano is a life sciences instrumentation company in the genome analysis space. The company develops and markets the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes, which is known as cytogenetics. The Saphyr system comprises an instrument, chip consumables, reagents and a suite of data analysis tools. The company is located in San Diego, California. For more information, please visit
(Source: Company Press Release | 8/21/18)

About ROTH Capital Partners
ROTH Capital Partners, LLC (ROTH), is a relationship-driven investment bank focused on serving emerging growth companies and their investors. As a full-service investment bank, ROTH provides capital raising, M&A advisory, analytical research, trading, market-making services and corporate access. Headquartered in Newport Beach, CA, ROTH is privately-held and employee owned, and maintains offices throughout the U.S. For more information on ROTH, please visit

Date of Announcement: 8/24/18

The material, information and  facts discussed in this announcement other than the information regarding ROTH Capital Partners, LLC ("ROTH") and its affiliates, are from sources believed to be reliable, but are in no way guaranteed to be complete or accurate. This announcement should not be used as a complete analysis of any companies, securities or topics discussed herein. Additional information is available upon request. This is not, however, an offer or solicitation of the securities discussed. Any opinions or estimates in this announcement are subject to change without notice. An investment in any security based on this announcement may involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Additionally, such investments may involve a high degree of risk and may not be suitable for all investors. No part of this announcement may be reproduced in any form without the express written permission of ROTH. Copyright 2018.